メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Catheter Ablation Outcomes and Life Expectancy in Very Elderly Atrial Fibrillation Patients: The REHEALTH AF Study

  • Shu Hirata
  • , Yasuo Okumura
  • , Koichi Nagashima
  • , Ryuta Watanabe
  • , Katsuaki Yokoyama
  • , Naoya Matsumoto
  • , Takeshi Kato
  • , Hidehira Fukaya
  • , Hidemori Hayashi
  • , Shiro Nakahara
  • , Wataru Shimizu
  • , Yu ki Iwasaki
  • , Yuhi Fujimoto
  • , Yasushi Mukai
  • , Koichiro Ejima
  • , Takayuki Otsuka
  • , Shinya Suzuki
  • , Masato Murakami
  • , Masaomi Kimura
  • , Masahide Harada
  • Junjiroh Koyama, Teiichi Yamane, Michifumi Tokuda, Mitsuru Takami, Morio Shoda, Tomoo Harada, Ikutaro Nakajima, Kenichi Hiroshima, Kojiro Tanimoto, Koji Kumagai, Ayako Okada, Hideki Kobayashi, Yuji Watari, Mina Hatsuno, Tatsuya Hayashi, Eizo Tachibana, Kazuki Iso, Kazumasa Sonoda, Yoshiyasu Aizawa, Ryoma Fukuoka, Akio Chikata, Masaru Inoue, Satoru Sakagami, Hitoshi Minamiguchi, Nobuhiko Makino, Makoto Ichikawa, Hironori Haruta, Takafumi Hiro, Kimie Okubo, Masaru Arai, Ken Arima, Hajime Kihara, Satoru Miyanaga, Yoshiaki Fukuda, Koji Oiwa, Yutaka Koyama, Tamami Kurihara, Masashi Akabane, Norikazu Ishikawa, Kengo Kusano, Koji Miyamoto, Haruna Tabuchi, Tomoyuki Shiozawa, Kenjiro Miyamoto, Hiroshi Mase, Kenta Murotani

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

Background: Evidence regarding the benefits of catheter ablation in patients aged ≥80 years with nonvalvular atrial fibrillation (AF) remains limited. Objectives: This study sought to evaluate the clinical effectiveness of catheter ablation compared with conservative management in elderly patients (age ≥80 years) with nonvalvular AF. Methods: This prospective, registry-based, multicenter observational study involved 703 patients aged ≥80 years with nonvalvular AF enrolled from 47 hospitals in Japan (June 2022-December 2023). Among them, 249 underwent catheter ablation and 454 received nonablation management. Results: The nonablation group was slightly older, with more comorbidities and modestly worse baseline characteristics; however, most were potential ablation candidates, and the differences were small. During a median follow-up of 504 days (Q1-Q3: 375-667 days), the primary outcome (a composite of stroke, transient ischemic attack, systemic embolism, cardiovascular events, bleeding, or all-cause death) did not differ between groups in the unmatched (HR: 0.78; P = 0.30) or matched (HR: 0.65; P = 0.21) cohorts. However, in the matched cohort, multivariable adjustment for log-N-terminal pro–B-type natriuretic peptide and albumin levels showed a significant benefit of ablation (adjusted HR: 0.44; P = 0.029). At 1 year, ablation improved symptoms, quality of life, N-terminal pro–B-type natriuretic peptide levels, and left atrial diameter, as well as better preservation of Mini–Mental State Examination and frailty scores. These benefits remained significant after adjustment. Conclusions: The REHEALTH AF Study (Registry for Evaluating Healthy Life Expectancy and Long-Term Outcomes After Catheter Ablation of Atrial Fibrillation in the Very Elderly) study is the first prospective comparison of ablation vs nonablation in patients aged ≥80 years with AF. Although ablation improved functional and structural outcomes, its prognostic benefit was limited without adjustment but emerged after multivariable correction. Ablation may offer meaningful advantages in well-selected elderly patients, supporting individualized treatment strategies.

本文言語英語
ページ(範囲)307-321
ページ数15
ジャーナルJACC: Clinical Electrophysiology
巻12
号2
DOI
出版ステータス出版済み - 02-2026

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 循環器および心血管医学
  • 生理学(医学)

フィンガープリント

「Catheter Ablation Outcomes and Life Expectancy in Very Elderly Atrial Fibrillation Patients: The REHEALTH AF Study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル